<b>Background</b>: Gefitinib (Gef) is a first-line epidermal growth factor receptor (EGFR) inhibitor for NSCLC, but its clinical application is limited by poor aqueous solubility and low oral bioavailability. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.